The Cigna Group (CI)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $78.26B
Last updated: Nov 17, 2026 at 11:05 AM ET
The Cigna Group (CI) Stock Forecast
Analysts expect The Cigna Group (CI) to earn $30.65 per share in the fiscal year ending Dec 31, 2026, on revenue of $288.54B. Of 24 analysts, 17 rate the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 20.8% |
| Buy | 12 | 50.0% |
| Hold | 7 | 29.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 24
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 8.5% and revenue estimates rise 3.7%.
- Fiscal year ending Dec 31, 2026
- $30.65
- EPS consensus, revenue $288.54B
- Fiscal year ending Dec 31, 2027
- $33.26
- EPS consensus, revenue $299.08B
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $30.65 | $30.49 to $31.01 | 22 | $288.54B | $286.03B to $291.00B | 15 |
| Dec 31, 2027 | $33.26 | $33.00 to $33.84 | 23 | $299.08B | $288.09B to $307.56B | 15 |
Quarterly Estimates
The EPS consensus rises from $7.32 for the quarter ending Dec 31, 2026 to $8.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.32 | $6.91 to $7.83 | 28 | $77.59B | $72.93B to $80.52B | 21 |
| Mar 31, 2027 | $8.35 | $7.89 to $9.00 | 15 | $71.46B | $69.66B to $76.43B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 4 |
| Quarter ending Mar 31, 2027 | 4 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.5% from $30.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $30.65 | $30.55 | $30.51 | $30.51 | $30.51 | +0.5% |
| Fiscal year ending Dec 31, 2027 | $33.26 | $33.46 | $33.48 | $33.49 | $33.47 | -0.6% |
| Quarter ending Mar 31, 2027 | $8.35 | $8.36 | $8.33 | $8.28 | $8.27 | +1.0% |
Frequently Asked Questions About CI
What is the CI stock forecast?
Consensus analyst estimates put The Cigna Group's EPS at $30.65 for the fiscal year ending Dec 31, 2026, on revenue of $288.54B. The consensus rating from 24 analysts is Buy.
How do analysts rate CI stock?
Of 24 analysts covering The Cigna Group, 5 rate it Strong Buy, 12 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $30.65, with estimates from $30.49 to $31.01 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $33.26, with estimates from $33.00 to $33.84 from 23 analysts.
What revenue do analysts expect from The Cigna Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $288.54B, with estimates from $286.03B to $291.00B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $299.08B, with estimates from $288.09B to $307.56B.
How many analysts cover CI?
24 analysts rate The Cigna Group stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CI pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors